Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

Company Overview

Edgewise Therapeutics (NASDAQ: EWTX) is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is focused on the discovery and development of small‐molecule therapeutics designed to activate chaperone‐mediated autophagy (CMA), a key cellular pathway for the selective degradation of misfolded or damaged proteins. By targeting this pathway, Edgewise aims to address the underlying biology of rare and debilitating genetic disorders that currently lack effective treatments.

The company’s lead development programs target enzyme‐deficient and muscle‐wasting disorders such as Pompe disease (glycogen storage disease type II) and certain forms of limb‐girdle muscular dystrophy. Edgewise’s proprietary platform enables the identification and optimization of compounds that enhance lysosomal function and promote the clearance of toxic protein aggregates. Preclinical studies have demonstrated the ability of these candidates to restore cellular homeostasis, and the company has advanced its most advanced compound into early‐stage clinical trials.

Founded in 2017 as a spin‐out from leading academic research laboratories, Edgewise has attracted venture funding from prominent life‐science investors and formed strategic research collaborations to support its translational pipeline. The company maintains research and development activities in both the United States and Europe, leveraging partnerships with contract research organizations and academic centers of excellence to conduct pharmacology, toxicology, and initial human studies. These alliances help to streamline the path from discovery to clinical proof‐of‐concept.

Edgewise’s leadership team comprises experienced executives and scientists with backgrounds in biotechnology, regulatory affairs, and commercial strategy. Drawing on prior roles at global pharmaceutical firms and specialized biotechs, the management group is committed to advancing innovative treatments for underserved patient populations. As Edgewise progresses through clinical milestones, it remains focused on delivering novel therapeutic options that harness the power of targeted protein degradation.

Key Stats

• Today's Range: $12.86 to $13.22
• 50-Day Range: $12.82 to $16.91
• 52-Week Range: $10.60 to $38.12
• Volume: 361,183 shs
• Average Volume: 1.19 million shs
• Market Capitalization: $1.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Moderate Buy

Edgewise Therapeutics Stock Analysis - MarketRank™

Edgewise Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 1423rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Edgewise Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edgewise Therapeutics is -8.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edgewise Therapeutics is -8.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edgewise Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.25% of the float of Edgewise Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Edgewise Therapeutics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Edgewise Therapeutics has recently decreased by 12.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edgewise Therapeutics does not currently pay a dividend.

Dividend Growth

Edgewise Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.25% of the float of Edgewise Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Edgewise Therapeutics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Edgewise Therapeutics has recently decreased by 12.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

Edgewise Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Edgewise Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,544.00 in company stock.

Percentage Held by Insiders

23.20% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

EWTX Stock Analysis - Frequently Asked Questions

How have EWTX shares performed this year?

Edgewise Therapeutics' stock was trading at $26.70 at the beginning of 2025. Since then, EWTX stock has decreased by 51.5% and is now trading at $12.9550.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.02.

When did Edgewise Therapeutics IPO?

Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edgewise Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EWTX
• CIK: 1710072
• Web: www.edgewisetx.com
• Phone: 720-262-7002
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.00
• High Stock Price Target: $51.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +208.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$133.81 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.95%
• Return on Assets: -29.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.99
• Quick Ratio: 20.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.84 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 105,200,000
• Free Float: 80,794,000
• Market Cap: $1.36 billion
• Optionable: Optionable
• Beta: 0.25